Drugs / Multi-epitope (ME) T-cell receptor g alternate reading frame protein (TARP) vaccine
Multi-epitope (ME) T-cell receptor g alternate reading frame protein (TARP) vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02362451 | Jul 2015 → Feb 2020 | prostate cancer | National Cancer Institute (NCI) | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Multi-epitope (ME) T-cell receptor g alternate reading frame protein (TARP) vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02362451 ↗ |
| Modality | Vaccine | “Multi-Epitope (ME) TARP Vaccine” NCT02362451 ↗ |